Fonar Corp
FONAR Corporation, sometimes referred to as the Company or FONAR , is a Delaware corporation which was incorporated on July 17, 1978. Our address is 110 Marcus Drive, Melville, New York 11747 and our telephone number is 631-694-2929.
$19.09
+$0.00 (+0.00%)
Price from 137 days ago
11.12% operating margin is respectable but not wide. ROIC at 4.05%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue growth slowed to 1.4%, essentially flat. This is a business that needs a catalyst.
Free cash flow declined 44% versus the prior year, cash generation momentum has weakened.
17.7x earnings, 25.7x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$105M
▲ +1.4% YoY
Net Income (TTM)
$7M
▼ -21.1% YoY
Op. Margin
9.05%
▲ +6.7pp YoY
ROIC
3.27%
▲ +2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$5M
▼ -43.8% YoY
Op. Cash Flow (TTM)
$8M
▼ -20.1% YoY
Net Debt
-$15M
Net Cash Position
Cash & Equiv.
$54M
5Y CAGR: +4.0%
5Y CAGR: -10.3%
Continue Research
SourceComputed from the 10-Q filed 11 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 3 Jun 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Fonar (FONR) overvalued?
At a P/E of 17.7 and a price-to-free-cash-flow of 25.7, Fonar (FONR) trades above a two-stage DCF intrinsic value of about $15.29 per share, so at $19.09 the stock looks overvalued (19.9% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Fonar scores 53/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Fonar's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $15.29 per share for FONR, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $11.46. At today's $19.09, that puts the stock about 19.9% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Fonar a high-quality business?+
Fonar scores 53 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 9.1% operating margin and a 3.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Fonar a good stock to buy right now?+
That depends on valuation and quality together, not either alone. FONR currently trades above its estimated intrinsic value and scores 53/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Electromedical & Electrotherapeutic Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.